Bayer CropScience Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 11:46 pm

Market Cap	21,711 Cr.
Current Price	4,842
High / Low	7,197/4,217
Stock P/E	41.7
Book Value	686
Dividend Yield	2.89 %
ROCE	33.9 %
ROE	26.7 %
Face Value	10.0
PEG Ratio	38.08

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Bayer CropScience Ltd

Competitors of Bayer CropScience Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Epigral Ltd	7,799 Cr.	1,808	2,408/940	22.5	324	0.28 %	17.5 %	16.9 %	10.0
Dharmaj Crop Guard Ltd	663 Cr.	197	390/165	19.6	117	0.00 %	14.5 %	13.2 %	10.0
Bhaskar Agrochemicals Ltd	39.6 Cr.	76.0	122/46.1	17.5	29.2	0.00 %	14.7 %	13.4 %	10.0
Bhagiradha Chemicals & Industries Ltd	3,872 Cr.	297	448/151	128	51.0	0.03 %	8.71 %	5.55 %	1.00
Best Agrolife Ltd	695 Cr.	296	756/246	36.0	320	1.01 %	16.5 %	18.1 %	10.0
Industry Average	10,095.70 Cr	1,496.05		35.79	421.93	0.41%	13.25%	14.87%	7.25

All Competitor Stocks of Bayer CropScience Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	990	963	1,667	1,452	1,038	982	1,740	1,617	955	792	1,631	1,738	1,057
Expenses	924	763	1,272	1,214	952	777	1,315	1,312	827	695	1,317	1,554	1,037
Operating Profit	66	201	395	238	85	206	425	305	128	97	314	184	20
OPM %	7%	21%	24%	16%	8%	21%	24%	19%	13%	12%	19%	11%	2%
Other Income	68	16	14	14	116	24	21	16	15	30	28	24	33
Interest	3	6	4	8	3	7	8	4	3	5	4	3	4
Depreciation	14	21	23	15	14	27	31	12	15	16	22	14	15
Profit before tax	118	190	382	229	184	195	406	306	124	105	316	190	34
Tax %	28%	19%	21%	29%	27%	19%	19%	27%	25%	9%	20%	28%	-2%
Net Profit	85	153	303	163	134	158	328	223	93	96	254	136	34
EPS in Rs	18.87	33.98	67.33	36.18	29.93	35.27	73.09	49.60	20.72	21.36	56.56	30.33	7.61

Last Updated: February 28, 2025, 1:05 pm

Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹1,057.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,738.00 Cr. (Sep 2024) to ₹1,057.00 Cr., marking a decrease of 681.00 Cr..
For Expenses, as of Dec 2024, the value is ₹1,037.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,554.00 Cr. (Sep 2024) to ₹1,037.00 Cr., marking a decrease of 517.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 184.00 Cr. (Sep 2024) to ₹20.00 Cr., marking a decrease of 164.00 Cr..
For OPM %, as of Dec 2024, the value is 2.00%. The value appears to be declining and may need further review. It has decreased from 11.00% (Sep 2024) to 2.00%, marking a decrease of 9.00%.
For Other Income, as of Dec 2024, the value is ₹33.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Sep 2024) to ₹33.00 Cr., marking an increase of ₹9.00 Cr..
For Interest, as of Dec 2024, the value is ₹4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Sep 2024) to ₹4.00 Cr., marking an increase of ₹1.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Sep 2024) to ₹15.00 Cr., marking an increase of ₹1.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Sep 2024) to ₹34.00 Cr., marking a decrease of 156.00 Cr..
For Tax %, as of Dec 2024, the value is -2.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to -2.00%, marking a decrease of 30.00%.
For Net Profit, as of Dec 2024, the value is ₹34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 136.00 Cr. (Sep 2024) to ₹34.00 Cr., marking a decrease of 102.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 7.61. The value appears to be declining and may need further review. It has decreased from ₹30.33 (Sep 2024) to 7.61, marking a decrease of ₹22.72.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:51 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	2,682	3,188	3,660	2,769	2,803	2,710	3,167	3,609	4,261	4,734	5,140	5,103	5,217
Expenses	2,321	2,768	3,144	2,334	2,389	2,300	2,684	2,883	3,450	3,923	4,216	4,147	4,603
Operating Profit	362	419	516	435	414	410	483	726	812	812	924	956	614
OPM %	13%	13%	14%	16%	15%	15%	15%	20%	19%	17%	18%	19%	12%
Other Income	1,242	91	88	82	70	39	51	-64	69	112	168	79	114
Interest	4	5	5	10	7	11	10	14	13	13	22	20	16
Depreciation	37	65	25	25	29	33	44	65	74	64	80	74	66
Profit before tax	1,563	441	574	482	448	404	480	583	794	847	990	941	645
Tax %	26%	34%	33%	35%	35%	26%	30%	19%	38%	24%	23%	21%
Net Profit	1,162	290	383	315	291	300	337	474	493	645	758	740	521
EPS in Rs	294.11	79.06	104.59	89.13	82.31	87.41	98.18	105.58	109.72	143.58	168.71	164.77	115.86
Dividend Payout %	2%	7%	20%	19%	21%	21%	18%	24%	105%	104%	77%	85%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-75.04%	32.07%	-17.75%	-7.62%	3.09%	12.33%	40.65%	4.01%	30.83%	17.52%	-2.37%
Change in YoY Net Profit Growth (%)	0.00%	107.11%	-49.82%	10.14%	10.71%	9.24%	28.32%	-36.64%	26.82%	-13.31%	-19.89%

Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 5:44 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	40	37	37	35	35	34	34	45	45	45	45	45	45
Reserves	1,892	1,706	1,996	1,804	2,021	1,744	2,205	2,528	2,505	2,479	2,667	2,804	3,037
Borrowings	0	0	0	0	0	0	0	2	26	86	74	47	33
Other Liabilities	484	645	740	597	769	756	1,310	1,262	1,663	1,742	1,893	1,701	2,155
Total Liabilities	2,415	2,387	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,270
Fixed Assets	219	228	322	290	342	334	440	468	425	468	462	414	516
CWIP	127	217	1	17	24	36	47	56	76	98	109	119	2
Investments	4	4	29	68	50	0	0	41	52	38	41	54	63
Other Assets	2,066	1,939	2,422	2,062	2,410	2,164	3,062	3,270	3,686	3,749	4,066	4,010	4,690
Total Assets	2,415	2,387	2,773	2,437	2,825	2,535	3,549	3,836	4,239	4,353	4,679	4,597	5,270

Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹45.00 Cr..
For Reserves, as of Sep 2024, the value is ₹3,037.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,804.00 Cr. (Mar 2024) to ₹3,037.00 Cr., marking an increase of 233.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹33.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹47.00 Cr. (Mar 2024) to ₹33.00 Cr., marking a decrease of 14.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹2,155.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,701.00 Cr. (Mar 2024) to ₹2,155.00 Cr., marking an increase of 454.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹5,270.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹4,597.00 Cr. (Mar 2024) to ₹5,270.00 Cr., marking an increase of 673.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹516.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹414.00 Cr. (Mar 2024) to ₹516.00 Cr., marking an increase of 102.00 Cr..
For CWIP, as of Sep 2024, the value is ₹2.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹119.00 Cr. (Mar 2024) to ₹2.00 Cr., marking a decrease of 117.00 Cr..
For Investments, as of Sep 2024, the value is ₹63.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹54.00 Cr. (Mar 2024) to ₹63.00 Cr., marking an increase of 9.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹4,690.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,010.00 Cr. (Mar 2024) to ₹4,690.00 Cr., marking an increase of 680.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹5,270.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,597.00 Cr. (Mar 2024) to ₹5,270.00 Cr., marking an increase of 673.00 Cr..

Notably, the Reserves (₹3,037.00 Cr.) exceed the Borrowings (33.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	138	282	200	206	157	121	433	666	687	216	609	952
Cash from Investing Activity +	427	-290	485	16	-8	38	-113	-29	7	64	83	0
Cash from Financing Activity +	-21	-480	-42	-590	-73	-581	-158	-148	-556	-703	-613	-656
Net Cash Flow	544	-488	644	-367	76	-421	162	489	138	-424	79	296

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	362.00	419.00	516.00	435.00	414.00	410.00	483.00	724.00	786.00	726.00	850.00	909.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	44	47	57	53	72	89	81	73	65	77	69	69
Inventory Days	106	98	85	169	178	175	294	206	226	235	268	222
Days Payable	42	51	40	52	67	67	164	101	142	127	129	87
Cash Conversion Cycle	108	94	102	171	184	197	211	177	149	185	208	204
Working Capital Days	79	88	53	92	104	134	116	77	62	87	89	80
ROCE %	29%	24%	31%	25%	23%	22%	25%	30%	31%	31%	34%	34%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	71.43%	71.43%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%	71.44%
FIIs	2.90%	2.95%	3.10%	3.19%	3.18%	3.18%	3.30%	3.53%	3.62%	3.63%	3.30%	3.42%
DIIs	12.90%	13.10%	12.76%	12.78%	12.74%	13.06%	13.23%	12.70%	12.80%	12.47%	12.08%	11.69%
Public	12.77%	12.51%	12.71%	12.59%	12.64%	12.32%	12.05%	12.33%	12.15%	12.47%	13.18%	13.45%
No. of Shareholders	60,230	57,760	57,896	57,048	57,253	48,404	45,329	46,907	45,852	46,201	51,289	54,289

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Mirae Asset Large & Midcap Fund	792,954	1.33	449.55	510,084	2025-03-11	55.46%
Nippon India Small Cap Fund	531,460	0.65	301.3	510,084	2025-03-11	4.19%
Mirae Asset Midcap Fund	510,084	1.99	289.18	510,084	2025-03-11	0%
Aditya Birla Sun Life ELSS Tax Saver Fund	392,896	1.48	222.75	510,084	2025-03-11	-22.97%
Aditya Birla Sun Life Frontline Equity Fund	329,435	0.71	186.77	510,084	2025-03-11	-35.42%
Nippon India Growth Fund	303,512	0.7	172.07	510,084	2025-03-11	-40.5%
HSBC Midcap Fund	294,959	1.72	167.22	510,084	2025-03-11	-42.17%
Aditya Birla Sun Life MNC Fund - Div	280,976	4.49	159.3	510,084	2025-03-11	-44.92%
Aditya Birla Sun Life MNC Fund - Gr	280,976	4.49	159.3	510,084	2025-03-11	-44.92%
Kotak Flexicap Fund - Regular Plan	215,000	0.27	121.89	510,084	2025-03-11	-57.85%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	164.77	168.71	143.58	109.72	105.58
Diluted EPS (Rs.)	164.77	168.71	143.58	109.72	105.58
Cash EPS (Rs.)	181.40	186.57	158.08	126.19	120.22
Book Value[Excl.RevalReserv]/Share (Rs.)	634.61	604.03	562.20	568.00	572.94
Book Value[Incl.RevalReserv]/Share (Rs.)	634.61	604.03	562.20	568.00	572.94
Dividend / Share (Rs.)	140.00	130.00	150.00	115.00	25.00
Revenue From Operations / Share (Rs.)	1136.57	1144.70	1054.43	949.06	803.88
PBDIT / Share (Rs.)	230.51	220.07	192.81	194.99	176.48
PBIT / Share (Rs.)	214.03	202.36	178.44	178.62	161.94
PBT / Share (Rs.)	209.66	220.51	188.60	176.95	129.87
Net Profit / Share (Rs.)	164.92	168.86	143.72	109.82	105.68
PBDIT Margin (%)	20.28	19.22	18.28	20.54	21.95
PBIT Margin (%)	18.83	17.67	16.92	18.82	20.14
PBT Margin (%)	18.44	19.26	17.88	18.64	16.15
Net Profit Margin (%)	14.51	14.75	13.63	11.57	13.14
Return on Networth / Equity (%)	25.98	27.95	25.56	19.33	18.44
Return on Capital Employeed (%)	32.03	31.31	29.74	30.05	26.96
Return On Assets (%)	16.10	16.20	14.82	11.63	12.37
Asset Turnover Ratio (%)	1.10	1.14	1.10	1.06	0.97
Current Ratio (X)	2.44	2.19	2.15	2.26	2.65
Quick Ratio (X)	1.48	1.18	1.24	1.41	1.80
Inventory Turnover Ratio (X)	1.48	1.39	1.82	2.17	1.65
Dividend Payout Ratio (NP) (%)	81.93	74.09	104.47	104.82	21.41
Dividend Payout Ratio (CP) (%)	74.48	67.06	94.98	91.22	18.82
Earning Retention Ratio (%)	18.07	25.91	-4.47	-4.82	78.59
Cash Earning Retention Ratio (%)	25.52	32.94	5.02	8.78	81.18
Interest Coverage Ratio (X)	52.81	44.31	67.11	69.48	57.42
Interest Coverage Ratio (Post Tax) (X)	38.78	30.35	46.49	39.73	44.82
Enterprise Value (Cr.)	22377.29	17307.30	21584.03	22612.20	14460.29
EV / Net Operating Revenue (X)	4.38	3.37	4.56	5.31	4.01
EV / EBITDA (X)	21.62	17.52	24.93	25.83	18.25
MarketCap / Net Operating Revenue (X)	4.61	3.54	4.73	5.59	4.30
Retention Ratios (%)	18.06	25.90	-4.47	-4.82	78.58
Price / BV (X)	8.26	6.70	8.86	9.34	6.04
Price / Net Operating Revenue (X)	4.61	3.54	4.73	5.59	4.30
EarningsYield	0.03	0.04	0.02	0.02	0.03

After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 164.77. This value is within the healthy range. It has decreased from 168.71 (Mar 23) to 164.77, marking a decrease of 3.94.
For Diluted EPS (Rs.), as of Mar 24, the value is 164.77. This value is within the healthy range. It has decreased from 168.71 (Mar 23) to 164.77, marking a decrease of 3.94.
For Cash EPS (Rs.), as of Mar 24, the value is 181.40. This value is within the healthy range. It has decreased from 186.57 (Mar 23) to 181.40, marking a decrease of 5.17.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 634.61. It has increased from 604.03 (Mar 23) to 634.61, marking an increase of 30.58.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 634.61. It has increased from 604.03 (Mar 23) to 634.61, marking an increase of 30.58.
For Dividend / Share (Rs.), as of Mar 24, the value is 140.00. This value exceeds the healthy maximum of 3. It has increased from 130.00 (Mar 23) to 140.00, marking an increase of 10.00.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,136.57. It has decreased from 1,144.70 (Mar 23) to 1,136.57, marking a decrease of 8.13.
For PBDIT / Share (Rs.), as of Mar 24, the value is 230.51. This value is within the healthy range. It has increased from 220.07 (Mar 23) to 230.51, marking an increase of 10.44.
For PBIT / Share (Rs.), as of Mar 24, the value is 214.03. This value is within the healthy range. It has increased from 202.36 (Mar 23) to 214.03, marking an increase of 11.67.
For PBT / Share (Rs.), as of Mar 24, the value is 209.66. This value is within the healthy range. It has decreased from 220.51 (Mar 23) to 209.66, marking a decrease of 10.85.
For Net Profit / Share (Rs.), as of Mar 24, the value is 164.92. This value is within the healthy range. It has decreased from 168.86 (Mar 23) to 164.92, marking a decrease of 3.94.
For PBDIT Margin (%), as of Mar 24, the value is 20.28. This value is within the healthy range. It has increased from 19.22 (Mar 23) to 20.28, marking an increase of 1.06.
For PBIT Margin (%), as of Mar 24, the value is 18.83. This value is within the healthy range. It has increased from 17.67 (Mar 23) to 18.83, marking an increase of 1.16.
For PBT Margin (%), as of Mar 24, the value is 18.44. This value is within the healthy range. It has decreased from 19.26 (Mar 23) to 18.44, marking a decrease of 0.82.
For Net Profit Margin (%), as of Mar 24, the value is 14.51. This value exceeds the healthy maximum of 10. It has decreased from 14.75 (Mar 23) to 14.51, marking a decrease of 0.24.
For Return on Networth / Equity (%), as of Mar 24, the value is 25.98. This value is within the healthy range. It has decreased from 27.95 (Mar 23) to 25.98, marking a decrease of 1.97.
For Return on Capital Employeed (%), as of Mar 24, the value is 32.03. This value is within the healthy range. It has increased from 31.31 (Mar 23) to 32.03, marking an increase of 0.72.
For Return On Assets (%), as of Mar 24, the value is 16.10. This value is within the healthy range. It has decreased from 16.20 (Mar 23) to 16.10, marking a decrease of 0.10.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.10. It has decreased from 1.14 (Mar 23) to 1.10, marking a decrease of 0.04.
For Current Ratio (X), as of Mar 24, the value is 2.44. This value is within the healthy range. It has increased from 2.19 (Mar 23) to 2.44, marking an increase of 0.25.
For Quick Ratio (X), as of Mar 24, the value is 1.48. This value is within the healthy range. It has increased from 1.18 (Mar 23) to 1.48, marking an increase of 0.30.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.48. This value is below the healthy minimum of 4. It has increased from 1.39 (Mar 23) to 1.48, marking an increase of 0.09.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 81.93. This value exceeds the healthy maximum of 50. It has increased from 74.09 (Mar 23) to 81.93, marking an increase of 7.84.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 74.48. This value exceeds the healthy maximum of 50. It has increased from 67.06 (Mar 23) to 74.48, marking an increase of 7.42.
For Earning Retention Ratio (%), as of Mar 24, the value is 18.07. This value is below the healthy minimum of 40. It has decreased from 25.91 (Mar 23) to 18.07, marking a decrease of 7.84.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 25.52. This value is below the healthy minimum of 40. It has decreased from 32.94 (Mar 23) to 25.52, marking a decrease of 7.42.
For Interest Coverage Ratio (X), as of Mar 24, the value is 52.81. This value is within the healthy range. It has increased from 44.31 (Mar 23) to 52.81, marking an increase of 8.50.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 38.78. This value is within the healthy range. It has increased from 30.35 (Mar 23) to 38.78, marking an increase of 8.43.
For Enterprise Value (Cr.), as of Mar 24, the value is 22,377.29. It has increased from 17,307.30 (Mar 23) to 22,377.29, marking an increase of 5,069.99.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.38. This value exceeds the healthy maximum of 3. It has increased from 3.37 (Mar 23) to 4.38, marking an increase of 1.01.
For EV / EBITDA (X), as of Mar 24, the value is 21.62. This value exceeds the healthy maximum of 15. It has increased from 17.52 (Mar 23) to 21.62, marking an increase of 4.10.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.61, marking an increase of 1.07.
For Retention Ratios (%), as of Mar 24, the value is 18.06. This value is below the healthy minimum of 30. It has decreased from 25.90 (Mar 23) to 18.06, marking a decrease of 7.84.
For Price / BV (X), as of Mar 24, the value is 8.26. This value exceeds the healthy maximum of 3. It has increased from 6.70 (Mar 23) to 8.26, marking an increase of 1.56.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.61, marking an increase of 1.07.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bayer CropScience Ltd as of March 12, 2025 is: ₹6,286.87

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Bayer CropScience Ltd is Undervalued by 29.84% compared to the current share price 4,842.00

Intrinsic Value of Bayer CropScience Ltd as of March 12, 2025 is: 6,355.71

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Bayer CropScience Ltd is Undervalued by 31.26% compared to the current share price 4,842.00

Last 5 Year EPS CAGR: 1.09%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 28.25%, which is a positive sign. The company has higher reserves (2,260.62 cr) compared to borrowings (20.62 cr), indicating strong financial stability. The company has shown consistent growth in sales (3.31 cr) and profit (586.92 cr) over the years.	The stock has a high average Working Capital Days of 88.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 165.83, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
1. Net Profit Margin: 14.51%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 32.03% (Industry Average ROCE: 13.25%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 25.98% (Industry Average ROE: 14.87%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 38.78
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.48
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 41.7 (Industry average Stock P/E: 35.79)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Bayer Cropscience Ltd. is a Public Limited Listed company incorporated on 09/09/1958 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24210MH1958PLC011173 and registration number is 011173. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company's Total Operating Revenue is Rs. 5103.20 Cr. and Equity Capital is Rs. 44.90 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Agro Chemicals/Pesticides	Bayer House, Central Avenue, Mumbai Maharashtra 400607	ir_bcsl@bayer.com http://www.bayer.in

Management
Name	Position Held
Mr. Pankaj Ramanbhai Patel	Chairman & Ind.Dire (Non-Exe)
Mr. Simon Thorsten Wiebusch	Vice Chairman & Mng.Director
Ms. Ketaki Sanat Bhagwati	Ind. Non-Executive Director
Mr. Sekhar Natarajan	Ind. Non-Executive Director
Mr. Simon Johannes Britsch	Executive Director & CFO
Dr. Thomas Hoffmann	Non Exe.Non Ind.Director
Dr. Miriam Holstein	Non Exe.Non Ind.Director
Ms. Radhika Rajan	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of Bayer CropScience Ltd?

The latest intrinsic value of Bayer CropScience Ltd as on 12 March 2025 is ₹6286.87, which is 29.84% higher than the current market price of 4,842.00, indicating the stock is undervalued by 29.84%. The intrinsic value of Bayer CropScience Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹21,711 Cr. and recorded a high/low of ₹7,197/4,217 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹3,037 Cr and total liabilities of ₹5,270 Cr.

What is the Market Cap of Bayer CropScience Ltd?

The Market Cap of Bayer CropScience Ltd is 21,711 Cr..

What is the current Stock Price of Bayer CropScience Ltd as on 12 March 2025?

The current stock price of Bayer CropScience Ltd as on 12 March 2025 is ₹4,842.

What is the High / Low of Bayer CropScience Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Bayer CropScience Ltd stocks is ₹7,197/4,217.

What is the Stock P/E of Bayer CropScience Ltd?

The Stock P/E of Bayer CropScience Ltd is 41.7.

What is the Book Value of Bayer CropScience Ltd?

The Book Value of Bayer CropScience Ltd is 686.

What is the Dividend Yield of Bayer CropScience Ltd?

The Dividend Yield of Bayer CropScience Ltd is 2.89 %.

What is the ROCE of Bayer CropScience Ltd?

The ROCE of Bayer CropScience Ltd is 33.9 %.

What is the ROE of Bayer CropScience Ltd?

The ROE of Bayer CropScience Ltd is 26.7 %.

What is the Face Value of Bayer CropScience Ltd?

The Face Value of Bayer CropScience Ltd is 10.0.